Apr 2023 $36 M Private placement after listing $10 to $50 million 40
PTC Therapeutics, Inc.: Private sale, Apr 2023 × Investors in this round 40 investors had bought by the notice of May 8, 2023: 40 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for PTC Therapeutics, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $36 M of $36 M offered
Smallest investment taken no minimum stated
What was sold equity, other: Common Stock Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Christine E. Utter · Executive Officer · Ms. Utter is the Senior Vice President, Chief Accounting Officer and Head of People Services of the Issuer. Emily E. Hill · Executive Officer · Ms. Hill is the Chief Financial Officer of the Issuer. Eric E. Pauwels · Executive Officer · Mr. Pauwels is the Chief Business Officer of the Issuer. Mark E. Boulding · Executive Officer · Mr. Boulding is the Executive Vice President and Chief Legal Officer of the Issuer. Matthew B. Klein, M.D. · Executive Officer, Director · Dr. Klein is the Chief Executive Officer and the Director of the Development Committee of the Issuer. Neil B. Almstead, Ph.D · Executive Officer · Dr. Almstead is the Chief Technical Operations Officer of the Issuer. Alethia P. Young · Director Allan D. Jacobson, Ph.D. · Director David P. Southwell · Director Emma B. Reeve · Director Glenn D. Steele Jr., M.D., Ph.D. · Director Jerome B. Zeldis, M.D., Ph.D. · Director Mary D. Smith · Director Michael B. Schmertzler · Director Stepanie S. Okey · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Mark E. Boulding, Executive Vice President and Chief Legal Officer. Source: SEC Form D, newest notice filed May 8, 2023. Read the notice at the SEC .
equity SEC May 2020 $42 M Private placement after listing $10 to $50 million 38
PTC Therapeutics, Inc.: Private sale, May 2020 × Investors in this round 38 investors had bought by the notice of Jun 12, 2020: 38 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for PTC Therapeutics, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $42 M of $42 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Christine S. Utter · Executive Officer Emily S. Hill · Executive Officer Eric S. Pauwels · Executive Officer Mark E. Boulding · Executive Officer Matthew S. Klein · Executive Officer Neil W. Almstead · Executive Officer Stuart W. Peltz · Executive Officer, Director Allan S. Jacobson · Director David P. Southwell · Director Dawn D. Svoronos · Director Emma S. Reeve · Director Glenn D. Steele, Jr. · Director Jerome B. Zeldis · Director Michael S. Schmertzler · Director Stephanie S. Okey · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Mark E. Boulding, Executive Vice President and Chief Legal Officer. Source: SEC Form D, newest notice filed Jun 12, 2020. Read the notice at the SEC .
equity SEC Apr 2020 $141 M Private placement after listing $50 to $250 million 57
PTC Therapeutics, Inc.: Private sale, Apr 2020 × Investors in this round 57 investors had bought by the notice of May 14, 2020: 57 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for PTC Therapeutics, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $141 M of $141 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $1,739,745
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Christine S. Utter · Executive Officer Emily S. Hill · Executive Officer Eric B. Pauwels · Executive Officer Mark E. Boulding · Executive Officer Matthew B. Klein · Executive Officer Neil W. Almstead · Executive Officer Stuart W. Peltz · Executive Officer, Director Allan S. Jacobson · Director David P. Southwell · Director Dawn D. Svoronos · Director Emma S. Reeve · Director Glenn D. Steele, Jr. · Director Jerome B. Zeldis · Director Michael S. Schmertzler · Director Stephanie S. Okey · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round SVB Leerink LLC (CRD 39011) · Boston, Massachusetts Sold in all US states Signed by Mark E. Boulding, Executive Vice President and Chief Legal Officer. Source: SEC Form D, newest notice filed May 14, 2020. Read the notice at the SEC .
equity SEC Aug 2018 $150 M Private placement after listing $50 to $250 million 52
PTC Therapeutics, Inc.: Private sale, Aug 2018 × Investors in this round 52 investors had bought by the notice of Sep 5, 2018: 52 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for PTC Therapeutics, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $150 M of $150 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Christine S. Utter · Executive Officer Marcio S. Souza · Executive Officer Mark E. Boulding · Executive Officer Neil W. Almstead · Executive Officer Stuart W. Peltz · Executive Officer, Director Allan S. Jacobson · Director David P. Southwell · Director Dawn D. Svoronos · Director Glenn D. Steele, Jr. · Director Jerome B. Zeldis · Director Michael S. Schmertzler · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Mark E. Boulding, Executive Vice President and Chief Legal Officer. Source: SEC Form D, newest notice filed Sep 5, 2018. Read the notice at the SEC .
equity SEC May 2013 $5 M No. 5 $2 to $10 million 1
PTC Therapeutics, Inc.: Raise no. 5, May 2013 × Investors in this round 1 investor had bought by the notice of May 15, 2013: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for PTC Therapeutics, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $5 M of $5 M offered
Smallest investment taken no minimum stated
What was sold equity
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $315,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Claudia W. Hirawat · Executive Officer Mark E. Boulding · Executive Officer Stuart W. Peltz · Executive Officer, Director Adam P. Koppel · Director Allan S. Jacobson · Director Axel P. Bolte · Director David P. Southwell · Director Geoffrey P. McDonough · Director Jerome B. Zeldis · Director Michael P. Kranda · Director Michael S. Schmertzler · Director Richard B. Aldrich · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Credit Suisse Securities (USA) LLC (CRD 816) · New York, New York Sold in CO Wedbush Securities Inc. (CRD 877) · Los Angeles, California Sold in CO Signed by Mark E. Boulding, Executive Vice President and Chief Legal Officer. Source: SEC Form D, newest notice filed May 15, 2013. Read the notice at the SEC .
equity SEC Mar 2013 $60 M No. 4 $50 to $250 million 32
PTC Therapeutics, Inc.: Raise no. 4, Mar 2013 × Investors in this round 32 investors had bought by the notice of Mar 21, 2013: 32 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for PTC Therapeutics, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $60 M of $60 M offered
Smallest investment taken no minimum stated
What was sold equity
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $3,149,970
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Claudia W. Hirawat · Executive Officer Mark E. Boulding · Executive Officer Stuart W. Peltz · Executive Officer, Director Adam P. Koppel · Director Allan S. Jacobson · Director Axel P. Bolte · Director David P. Southwell · Director Geoffrey P. McDonough · Director Jerome B. Zeldis · Director Michael P. Kranda · Director Michael S. Schmertzler · Director Richard B. Aldrich · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Wedbush Securities Inc. (CRD 877) · Los Angeles, California Sold in CA, CT, MA, NJ, NY Credit Suisse Securities (USA) LLC (CRD 816) · New York, New York Sold in CA, CT, DC, IL, MA, MD, NJ, NY, PA Signed by Mark E. Boulding, Executive Vice President and Chief Legal Officer. Source: SEC Form D, newest notice filed Mar 21, 2013. Read the notice at the SEC .
equity SEC Jan 2013 $2 M No. 3 $2 to $10 million 25
PTC Therapeutics, Inc.: Raise no. 3, Jan 2013 × Investors in this round 25 investors had bought by the notice of Feb 12, 2013: 25 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for PTC Therapeutics, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $2 M of $16 M offered; $14 M still to sell
Smallest investment taken no minimum stated
What was sold debt, options or other rights to buy securities
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Claudia W. Hirawat · Executive Officer Mark E. Boulding · Executive Officer Stuart W. Peltz · Executive Officer, Director Allan S. Jacobson · Director Axel P. Bolte · Director David P. Southwell · Director Deepa P. Pakianathan · Director Geoffrey P. McDonough · Director Jerome B. Zeldis · Director Michael P. Kranda · Director Michael S. Schmertzler · Director Peter P. Svennilson · Director Soren P. Carlsen · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Mark E. Boulding, Executive Vice President and Chief Legal Officer. Source: SEC Form D, newest notice filed Feb 12, 2013. Read the notice at the SEC .
debt, options SEC May 2012 $23 M No. 2 $10 to $50 million 27
PTC Therapeutics, Inc.: Raise no. 2, May 2012 × Investors in this round 27 investors had bought by the notice of Jun 13, 2012: 27 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for PTC Therapeutics, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $23 M of $40 M offered; $17 M still to sell
Smallest investment taken no minimum stated
What was sold equity
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Claudia W. Hirawat · Executive Officer Mark E. Boulding · Executive Officer Stuart W. Peltz · Executive Officer, Director Allan S. Jacobson · Director Axel P. Bolte · Director Carl P. Goldfischer · Director David P. Southwell · Director Deepa P. Pakianathan · Director Michael P. Kranda · Director Michael S. Schmertzler · Director Peter P. Svennilson · Director Soren P. Carlsen · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Mark E. Boulding, Executive Vice President and Chief Legal Officer. Source: SEC Form D, newest notice filed Jun 13, 2012. Read the notice at the SEC .
equity SEC Dec 2009 $25 M No. 1 $10 to $50 million 21
PTC Therapeutics, Inc.: Raise no. 1, Dec 2009 × Investors in this round 21 investors had bought by the notice of Dec 22, 2009: 21 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for PTC Therapeutics, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $25 M of $50 M offered; $25 M still to sell
Smallest investment taken no minimum stated
What was sold equity
Meant to last a year or less
Issuer's revenue $25 million to $100 million
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Langdon L. Miller · Executive Officer Mark E. Boulding · Executive Officer Stuart W. Peltz · Executive Officer, Director William E. Baird, III · Executive Officer Allan S. Jacobson · Director Axel P. Bolte · Director Carl P. Goldfischer · Director David P. Southwell · Director Deepa P. Pakianathan · Director Michael P. Kranda · Director Michael S. Schmertzler · Director Soren P. Carlsen · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Mark E. Boulding, Senior Vice President and General Counsel. Source: SEC Form D, newest notice filed Dec 22, 2009. Read the notice at the SEC .
equity SEC